GVR Report cover U.S. Contraceptive Market Size, Share & Trends Report

U.S. Contraceptive Market Size, Share & Trends Analysis Report By Product (Pills, Condoms, Vaginal Ring, Subdermal Implants, IUD, Injectable), And Segment Forecasts, 2020 - 2027

  • Published Date: Dec, 2020
  • Base Year for Estimate: 2019
  • Report ID: GVR-2-68038-702-5
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2018
  • Number of Pages: 80

Report Overview

The U.S. contraceptive market size was valued at around USD 7 billion in 2019 and is projected to grow at a compound annual growth rate (CAGR) of around 4% over the forecast period. Increasing awareness regarding the importance of sexual and reproductive health in women in the age group of 15-49 years is expected to boost the use of various birth control methods. Modern contraceptive methods, such as condoms, pills, and implants, are preferred by women of the age group 15 to 29 years. In 2018, 43 million women in the U.S. were at the risk of unintended pregnancy. According to the CDC, 19.5 million women still lack access to healthcare centers offering a full range of contraceptive methods.

The U.S. contraceptive market size, by product, 2016 - 2027 (USD Billion)

Women living in smaller counties have limited access to modern birth control, which leads to unwanted pregnancy or abortion. Thus, increasing demand for contraceptives is likely to aid market growth. According to the Patient Protection and Affordable Care Act, all contraceptive methods authorized by the FDA must be covered by private insurance. The federal and state governments also provide reimbursements for family planning services and supplies to help women.

The Center for Medicaid and CHIP Services (CMCS) established a Maternal and Infant Health Initiative for the Medicaid and Children’s Health Insurance Program (CHIP) to promote the use of effective methods of contraception. Such government initiatives to improve family planning and reproductive health has significantly increased awareness and use of contraceptive in the U.S. Moreover, the availability of new and advanced contraceptive methods is anticipated to increase the adoption of contraceptives.

The Covid-19 pandemic has significantly impacted the U.S. healthcare sector. The contraceptives market is majorly dependent on physician-prescribed and physician-administered products. Due to restrictions on visiting physician offices without an emergency, the demand for contraceptive products was low during the first few months of the pandemic. Telehealth services and virtual consultations were recommended for contraceptive screening and counseling.

Product Insights

In 2019, the pills segment led the market accounting for the largest revenue share of over 40% as pills were the most common and popular contraceptive method due to their convenience of use. However, Long-Acting Reversible Contraceptives (LARCs), such as subdermal implants, are projected to witness significant growth during the forecast period due to more than 99.0% effectivity, cost-efficiency, and quick return of natural fertility after removal. Condom use has significantly increased in adolescents due to easy availability and convenience. Furthermore, effective protection from sexually transmitted infections and demand from the young population are expected to aid the segment growth.

The condom market in the U.S. is dominated by a few market leaders that include Church & Dwight (Trojan), Reckitt Benckiser (Durex), and Lifestyles. The availability of different variants under the brands with high-quality standards, cost-effectiveness, and easy access from supermarkets, drug stores, and e-commerce platforms are expected to help these brands in sustaining their position in the market.

The U.S. contraceptive market share, by product, 2019 (%)

The Intrauterine Devices (IUDs) segment also accounted for a significant share in 2019 and is expected to witness lucrative growth. This can be attributed to long-term reversible protection from pregnancy and the availability of nonhormonal products. ParaGuard, Mirena, and Liletta are the available IUDs in the U.S. market. The vaginal rings segment is also expected to register a considerable growth from 2020 to 2027.

Vaginal rings are polymeric devices designed to allow controlled release of drugs via intravaginal administration over an extended time to prevent pregnancy. It is a self-administered method used once a month. The ring is a simple, convenient, and safe method to prevent pregnancy. The vaginal ring also helps protect against infection of ovaries, prevent the development of acne, and prevent heavy/irregular periods, bone thinning, premenstrual symptoms, & menstrual cramps.

Key Companies & Market Share Insights

The regional market is highly competitive due to the presence of several companies. Most of the companies are undertaking strategic initiatives, such as investments in R&D for developing innovative products and to gain a competitive edge over others.

In February 2020, Afaxys, Inc. and TherapeuticsMD, Inc. signed an agreement to increase access to Annovera in the U.S. public healthcare system. In July 2020, TherapeuticsMD, Inc. entered into an agreement with Nurx—an online company for women’s health—for increasing its access to Annovera. High investments by prominent companies for the commercialization of effective and long-term reversible contraceptives have increased the awareness levels about these products. Some of the prominent companies in the U.S. contraceptive market include:

  • Church & Dwight Co., Inc.

  • Reckitt Benckiser Group Plc

  • Veru, Inc.

  • Merck & Co., Inc.

  • Pfizer, Inc.

  • Teva Pharmaceutical Industries Ltd.

  • The Cooper Companies, Inc.

  • Mayer Laboratories, Inc.

  • Agile Therapeutics

  • TherapeuticsmMD, Inc.

  • Allergan

  • Bayer Ag

  • Afaxys, Inc.

  • Mithra Pharmaceuticals

  • Blairex Laboratories, Inc.

  • Sebela Pharmaceuticals

  • Mona Lisa

  • Pregna International Ltd.

  • Prosan International B.V.

  • Smb Corporation Of India

  • Abbvie

  • Melbea Innovations Ltd.

  • Dkt International

  • Ocon Healthcare

U.S. Contraceptive Market Report Scope

Report Attribute


Market size value in 2020

USD 7.35 Billion

Revenue forecast in 2027

USD 9.91 Billion

Growth Rate

CAGR of 4.3% from 2020 to 2027

Base year for estimation


Historical data

2016 - 2018

Forecast period

2020 - 2027

Quantitative units

Revenue in USD million/billion and CAGR from 2020 to 2027

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered


Country scope


Key companies profiled

Church & Dwight Co., Inc.; Reckitt Benckiser Group Plc; Veru, Inc.; Merck & Co., Inc.; Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; The Cooper Companies, Inc.; Mayer Laboratories, Inc.; Agile Therapeutics; TherapeuticsMD, Inc.; Allergan; Bayer Ag; Afaxys, Inc.; Mithra Pharmaceuticals; Blairex Laboratories, Inc.; Sebela Pharmaceuticals; Mona Lisa; Pregna International Ltd.; Prosan International B.V.; Smb Corporation of India; Abbvie; Melbea Innovations Ltd.; Dkt International; Ocon Healthcare

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope

Pricing and purchase options

Avail of customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For this study, Grand View Research has segmented the U.S. contraceptive market report on the basis of product:

  • Product Outlook (Revenue, USD Million, 2016 - 2027)

    • Pills

    • IUD

      • Hormonal IUD

      • Nonhormonal IUD

    • Condoms

    • Vaginal Ring

    • Subdermal Implants

    • Injectable

    • Others

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.